サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793799

ロザイ・ドルフマン病の世界市場

Rosai-Dorfman Disease

出版日
ページ情報
英文 372 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ロザイ・ドルフマン病の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ロザイ・ドルフマン病の世界市場は2030年までに8億4,700万米ドルに達する見込み

2024年に6億2,780万米ドルと推定されるロザイ・ドルフマン病の世界市場は、2030年には8億4,700万米ドルに達し、分析期間2024-2030年のCAGRは5.1％で成長すると予測されます。本レポートで分析したセグメントの1つであるクラシックロザイ・ドルフマン病は、CAGR 4.0%を記録し、分析期間終了時には4億7,760万米ドルに達すると予測されます。域外ロザイ・ドルフマン病セグメントの成長率は分析期間でCAGR 6.8％と推定されます。

米国市場は1億7,100万米ドル、中国はCAGR 7.9％で成長予測

米国のロザイ・ドルフマン病市場は、2024年に1億7,100万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億6,660万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6％と5.0％と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

世界のロザイ・ドルフマン病市場- 主要動向と促進要因まとめ

希少疾患の解読：診断の向上と標的治療がロザイ・ドルフマン治療の展望をどのように再構築しているか

ロザイ・ドルフマン病とは何か、なぜ診断と治療が課題なのか？

ロザイ・ドルフマン病（RDD）、または巨大リンパ節腫脹を伴う洞組織球症は、リンパ節および節外組織における組織球の過剰産生と蓄積を特徴とするまれな非ランゲルハンス細胞組織球症です。多くの場合、無痛性の頸部リンパ節腫脹を呈するが、皮膚、呼吸器、中枢神経系および他の臓器に浸潤することもあり、診断が曖昧になりやすいです。本疾患は、リンパ腫や全身性自己免疫疾患などの悪性腫瘍を模倣することがあり、早期かつ正確な診断を困難にしています。

RDDの発症機序は、免疫調節異常や感染性の誘因が関与している可能性が疑われているが、まだ十分に解明されていないです。緩徐なリンパ節腫大から侵攻性の多臓器病変まで、その病像は多様であるため、治療戦略も複雑です。伝統的に、この疾患は自然寛解の可能性があるため保存的に管理されてきました。しかし、重要な臓器に病変があったり、外観を損なうような進行がみられたりする場合には、コルチコステロイド、免疫抑制剤、外科的治療が必要となります。KRASやNRASのような分子変異を有する患者において、MEK阻害剤を含む標的治療の有用性が新たなエビデンスによって示されており、より個別化された治療の未来が指し示されています。

診断の革新はRDDの臨床状況をどのように変えているか？

病理組織学的解析は、エンペリポレシスやS100+組織球などの特徴的な特徴を持つロザイ・ドルフマン病を診断するためのゴールドスタンダードであり続けています。しかし、最近の分子診断学や画像診断の進歩により、早期発見、亜分類、モニタリングが改善されつつあります。全エクソーム塩基配列決定（WES）と次世代塩基配列決定（NGS）により、RDD患者の一部でMAPK/ERK経路の再発性変異が発見され、分子病因と潜在的な治療反応性に基づく層別化が可能になりました。

画像診断は、疾患の程度と治療効果を評価する上で極めて重要な役割を果たしています。陽電子放射断層撮影法（PET-CT）は、活動性病変の同定、生検のガイド、残存病変のモニタリングにますます使用されるようになっています。他の組織球性疾患や肉芽腫性疾患との鑑別が重要な中枢神経系病変の場合は、MRIが望ましいです。さらに、疾患活動性と治療効果を追跡するための循環バイオマーカーとサイトカインプロファイリングが研究されています。

このような診断の進歩は、早期の介入を支援し、不必要な外科的切除を回避し、分子リスクプロファイルに基づいた治療のエスカレーションを導くことによって、臨床管理を再構築しつつあります。診断の標準化は、この病気が稀少であること、また臨床医の習熟度や診断へのアクセスに地理的なばらつきがあることを考えると、特に重要です。

RDDの影響を最も受ける患者グループとヘルスケア市場は？

RDDは世界的に分布していますが、小児、青年、若年成人に多く、やや男性優位です。特に、高度な画像診断や組織学的専門知識へのアクセスが制限されている低リソース環境では、ほとんど報告されていません。多くの症例はリンパ節転移に限定され、介入することなく治癒するが、かなりの割合（40％）が節外浸潤を示し、積極的な管理を必要とします。

RDD診断薬と治療薬の市場は、北米、欧州、東アジアの三次医療センター、大学病院、血液腫瘍専門クリニックで顕著です。米国と日本は臨床研究に強い関心を示しており、学術的な登録や複数の機関によるコホートが、この疾患の臨床スペクトラムや治療成績の定義に役立っています。希少疾病を専門とする製薬企業もパイプラインを拡充しており、特に変異陽性症例において、RDD治療に再利用できる可能性のある治験薬が含まれています。

患者支援団体、希少疾患財団、政府主催の研究イニシアチブは、疾患認識、診断の公平性、実験的治療へのアクセスの改善において重要な役割を果たしています。このことは、診断の遅れによって転帰がより悪くなることが多い、十分なサービスを受けていない地域や世界の地域にとって特に重要です。

ロザイ・ドルフマン病市場の原動力は？

ロザイ・ドルフマン病市場の成長は、特に分子診断の進歩、医師の意識の向上、ターゲットを絞った個別化治療プロトコールへのシフトなど、いくつかの要因によって牽引されています。RDD患者の一部で実用化可能な変異が発見されたことで、MEK阻害剤、免疫チェックポイント阻害剤、マクロファージ活性化を調節する生物学的製剤を含む臨床試験の扉が開かれました。このことは、RDD市場を、経験的治療に代わって精密医療が行われる希少疾患治療におけるより広範な動向と一致させるものです。

出版活動の活発化、世界のRDD登録の確立、組織球性疾患に対する集学的腫瘍委員会の採用により、診断率と治療経路が改善されつつあります。新興経済諸国の医療制度は、希少疾病用医薬品開発にインセンティブを与える有利な規制の枠組みにも助けられ、希少疾病用医薬品により多くのリソースを割り当てています。また、組織球症の分類システムや診断アルゴリズムにRDDが含まれることで、一般開業医や専門医の早期スクリーニングや認知が促されています。

最後に、デジタル病理学、AIを活用した生検解釈、共同研究ネットワークの融合は、診断のばらつきを減らし、治療イノベーションを加速させる。RDDが謎めいた希少疾患から、ゲノム的に特徴付けられ、臨床的に層別化された疾患へと移行するにつれ、市場は、世界中の主要な医療システムにおいて、医薬品開発、臨床試験、精密診断の機会が拡大することになります。

セグメント

タイプ（古典的ロザイ・ドルフマン病,節外ロザイ・ドルフマン病）;投与経路（経口投与,非経口投与,その他の投与経路）;エンドユーザー（病院・診療所エンドユーザー,外来手術センターエンドユーザー,その他のエンドユーザー）

調査対象企業の例

  • Amgen
  • Amicus Therapeutics
  • AstraZeneca
  • Bayer
  • BMS（Bristol-Myers Squibb）
  • GSK（GlaxoSmithKline）
  • Janssen（Johnson & Johnson）
  • Kura Oncology
  • Merck & Co.
  • Novartis
  • Pfizer
  • Protalix BioTherapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Takeda
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Blueprint Medicines
  • Incyte

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37947

Global Rosai-Dorfman Disease Market to Reach US$847.0 Million by 2030

The global market for Rosai-Dorfman Disease estimated at US$627.8 Million in the year 2024, is expected to reach US$847.0 Million by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Classic Rosai-Dorfman Disease, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$477.6 Million by the end of the analysis period. Growth in the Extranodal Rosai-Dorfman Disease segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$171.0 Million While China is Forecast to Grow at 7.9% CAGR

The Rosai-Dorfman Disease market in the U.S. is estimated at US$171.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$166.6 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Rosai-Dorfman Disease Market - Key Trends & Drivers Summarized

Decoding a Rare Disease: How Better Diagnostics and Targeted Therapies Are Reshaping Rosai-Dorfman Treatment Landscape

What Is Rosai-Dorfman Disease and Why Is It Challenging to Diagnose and Treat?

Rosai-Dorfman Disease (RDD), or sinus histiocytosis with massive lymphadenopathy, is a rare non-Langerhans cell histiocytosis characterized by overproduction and accumulation of histiocytes in lymph nodes and extranodal tissues. It often presents with painless cervical lymphadenopathy but may involve the skin, respiratory tract, central nervous system, and other organs, leading to significant diagnostic ambiguity. The disease can mimic malignancies such as lymphoma or systemic autoimmune disorders, making early and accurate diagnosis difficult.

RDD’s pathogenesis remains poorly understood, though it is suspected to involve immune dysregulation or infectious triggers. The heterogeneity in presentation-ranging from indolent lymph node enlargement to aggressive, multi-organ involvement-complicates treatment strategies. Traditionally, the disease has been managed conservatively due to its potential for spontaneous remission. However, in cases of vital organ involvement or disfiguring progression, corticosteroids, immunosuppressants, or surgical intervention may be warranted. Emerging evidence has shown the utility of targeted therapies, including MEK inhibitors, in patients with molecular mutations such as KRAS or NRAS, pointing toward a more personalized treatment future.

How Is Diagnostic Innovation Transforming the Clinical Landscape for RDD?

Histopathological analysis remains the gold standard for diagnosing Rosai-Dorfman Disease, with hallmark features such as emperipolesis and S100+ histiocytes. However, recent advances in molecular diagnostics and imaging modalities are improving early detection, subclassification, and monitoring. Whole exome sequencing (WES) and next-generation sequencing (NGS) have uncovered recurrent mutations in the MAPK/ERK pathway in a subset of RDD patients, allowing stratification based on molecular etiology and potential therapy responsiveness.

Imaging plays a pivotal role in evaluating disease extent and therapeutic response. Positron emission tomography-computed tomography (PET-CT) is increasingly used to identify active lesions, guide biopsies, and monitor residual disease. MRI is preferred in cases of central nervous system involvement, where differentiation from other histiocytic or granulomatous diseases is critical. Additionally, circulating biomarkers and cytokine profiling are under investigation for tracking disease activity and treatment efficacy-tools that could help move toward less invasive longitudinal care models.

These diagnostic advancements are reshaping clinical management by supporting earlier intervention, avoiding unnecessary surgical excisions, and guiding treatment escalation based on molecular risk profiles. Diagnostic standardization is particularly important given the disease’s rarity and geographical variability in clinician familiarity and diagnostic access.

Which Patient Groups and Healthcare Markets Are Most Affected by RDD?

RDD has a global distribution but is more commonly diagnosed in children, adolescents, and young adults, with a slight male predominance. It remains largely underreported, especially in low-resource settings where access to advanced imaging and histological expertise is limited. While many cases are limited to lymph nodes and resolve without intervention, a significant proportion-up to 40%-show extranodal involvement requiring aggressive management.

The market for RDD diagnostics and therapeutics is more pronounced in tertiary care centers, academic hospitals, and specialty hematology-oncology clinics in North America, Europe, and East Asia. The U.S. and Japan have shown strong clinical research interest, with academic registries and multi-institutional cohorts helping to define the disease’s clinical spectrum and treatment outcomes. Pharmaceutical companies focusing on rare diseases are also expanding their pipelines to include investigational drugs that could potentially be repurposed for RDD treatment, particularly in mutation-positive cases.

Patient advocacy groups, rare disease foundations, and government-sponsored research initiatives are playing a crucial role in improving disease awareness, diagnostic equity, and access to experimental therapies. This is particularly important for underserved communities and global regions where delayed diagnosis often results in poorer outcomes.

What Is Driving the Momentum in the Rosai-Dorfman Disease Market?

The growth in the Rosai-Dorfman Disease market is driven by several factors, notably advances in molecular diagnostics, increased physician awareness, and a shift toward targeted and individualized treatment protocols. The discovery of actionable mutations in a subset of RDD patients has opened the door for clinical trials involving MEK inhibitors, immune checkpoint blockers, and biologics that modulate macrophage activation. This aligns the RDD market with broader trends in rare disease therapeutics where precision medicine is replacing empiric treatment.

Increased publication activity, establishment of global RDD registries, and the adoption of multidisciplinary tumor boards for histiocytic disorders are improving diagnostic rates and care pathways. Health systems in developed economies are allocating more resources for orphan diseases, aided by favorable regulatory frameworks that incentivize orphan drug development. The inclusion of RDD in histiocytosis classification systems and diagnostic algorithms is also encouraging earlier screening and recognition among general practitioners and specialists alike.

Lastly, the convergence of digital pathology, AI-enabled biopsy interpretation, and collaborative research networks is set to reduce diagnostic variability and accelerate therapeutic innovation. As RDD shifts from an enigmatic and rare disorder to a genomically characterized and clinically stratified disease, the market will see expanded opportunities for pharmaceutical development, clinical trials, and precision diagnostics across key healthcare systems worldwide.

SCOPE OF STUDY:

The report analyzes the Rosai-Dorfman Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Classic Rosai-Dorfman Disease, Extranodal Rosai-Dorfman Disease); Administration Route (Oral Administration, Parenteral Administration, Other Administration Routes); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amgen
  • Amicus Therapeutics
  • AstraZeneca
  • Bayer
  • BMS (Bristol-Myers Squibb)
  • GSK (GlaxoSmithKline)
  • Janssen (Johnson & Johnson)
  • Kura Oncology
  • Merck & Co.
  • Novartis
  • Pfizer
  • Protalix BioTherapeutics
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Takeda
  • Ultragenyx Pharmaceutical
  • Vertex Pharmaceuticals
  • Blueprint Medicines
  • Incyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rosai-Dorfman Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnostic Awareness Among Clinicians Throws the Spotlight on Rare Histiocytic Disorders
    • Expansion of Immunohistochemistry and Genetic Profiling Drives Precision in Disease Classification
    • Growth in Rare Disease Registries and Patient Advocacy Strengthens Business Case for Targeted Therapies
    • Increased Availability of Advanced Imaging Tools Propels Early Diagnosis and Monitoring
    • Emerging Research on Immune Dysregulation in Histiocytosis Expands Treatment Pathways
    • Collaborations Between Academic Hospitals and Biotech Firms Accelerate Clinical Understanding
    • Wider Access to Molecular Diagnostic Panels Enhances Disease Subtyping and Case Differentiation
    • Inclusion in Rare Disease Policy Frameworks Generates Reimbursement and Funding Opportunities
    • Off-Label Use of Immunosuppressants and Targeted Therapies Spurs Clinical Trials
    • Growing Emphasis on Non-Langerhans Cell Histiocytosis Drives Demand for Novel Drug Candidates
    • Increased Recognition in Pediatric and Young Adult Populations Expands Diagnostic Vigilance
    • Integration of Electronic Health Records in Rare Disease Tracking Enhances Epidemiological Data
    • Patient-Centric Research Initiatives Propel Compassionate Access to Experimental Therapies
    • Cross-Disciplinary Collaboration in Rheumatology, Oncology, and Pathology Enhances Multimodal Care
    • Genetic Sequencing Studies Strengthen Understanding of Etiopathogenesis and Biomarkers
    • Rising Demand for Case-Based Learning Modules Drives Education in Rare Disease Medicine
    • Market Entry of Specialty Pharma Firms Into Orphan Disease Segments Expands Treatment Pipeline
    • Surge in AI-Based Differential Diagnosis Tools Supports Identification of Atypical Presentations
    • Regulatory Incentives for Orphan Drug Development Propel Innovation in Treatment Strategies
    • Growth in Global Medical Conference Discourse Enhances Awareness and Clinical Reporting
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rosai-Dorfman Disease Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Classic Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Classic Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Classic Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Extranodal Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Extranodal Rosai-Dorfman Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Extranodal Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Rosai-Dorfman Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Rosai-Dorfman Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Rosai-Dorfman Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Rosai-Dorfman Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Rosai-Dorfman Disease by Type - Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Rosai-Dorfman Disease by Type - Percentage Breakdown of Value Sales for Classic Rosai-Dorfman Disease and Extranodal Rosai-Dorfman Disease for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Rosai-Dorfman Disease by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Rosai-Dorfman Disease by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Rosai-Dorfman Disease by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Rosai-Dorfman Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION